An orally active small-molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1) could provide a novel therapeutic strategy for renal and cardiovascular diseases. Here, authors from Ewha Womans University, Seoul review current understanding of the role of PAI-1 in renal fibrosis and intimal hyperplasia, with a particular focus on the regulation of PAI-1 expression by reactive oxygen species. They also discuss the progress that has been made toward achieving therapeutic suppression of PAI-1.
- Hunjoo Ha
- Eun Y. Oh
- Hi B. Lee
